Featured Clinical Trial:

Non-small cell lung cancer (product/compound: Pemetrexed; Paclitaxel; Carboplatin; Bevacizumab)

ClinicAid Locations: Southern California – Fountain Valley

Status: Enrollment closed.

Condition: Non-Small Cell Lung Cancer

Product Name/Compound: Pemetrexed; Paclitaxel; Carboplatin; Bevacizumab

Full Study Title: Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer

Study Summary: Compare overall survival in patients with Stage IIIB or IV Nonsquamous non-small cell lung cancer

Eligible Participants:

Inclusion (Eligible):

Have Stage IIIB or Stage IV nonsquamous non-small cell lung cancer.
Have not received any prior treatment for your disease.
Prior radiation therapy is allowed to &ly; 25% of the bone marrow; however, prior radiation to the whole pelvis is not allowed. If you have had radiation therapy to the chest, you are not eligible to participate.
Must be at least 18 years of age or older.
Must have measureable tumor lesions or disease can be evaluated on CT scan

Exclusion (Not Eligible):

Have clinically significant third-space fluid collections (e.g. ascites or pleural effusions that cannot be controlled by drainage or other procedures).
Have NSCLC of predominantly squamous cell histology.
Have known central nervous system (CNS) disease, other than stable, treated brain metastasis.
Have undergone a surgical procedure, open biopsy, open pleurodesis, or significant traumatic injury within 28 days of starting the study treatment, or have an anticipated need for major surgery during the study.
Have a history of gastrointestinal fistula, perforation, or abscess, inflammatory bowel disease, or diverticulitis.
Currently receiving ongoing treatment with full-dose warfarin or equivalent.
Have significant vascular disease, serious cardiac conditions (such as heart attack), stroke or transient ischemic attack within 6 months of the trial.
Have evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation).
Have inadequately controlled hypertension, or a history of hypertensive crisis or hypertensive encephalopathy.
Have a serious, nonhealing wound, active ulcer, or untreated bone fracture.
Have another form of cancer, other than superficial basal cell and superficial squamous (skin) cell, or carcinoma in situ of the cervix within the last 5 years.
Have previously received treatment with paclitaxel, carboplatin, pemetrexed, or bevacizumab.
Have a known sensitivity to any component of paclitaxel, carboplatin, pemetrexed, or bevacizumab.
Have a history of hemoptysis (coughing blood) within 3 months prior to the trial.
Unable to stop taking aspirin more than 1.3 grams per day or other nonsteroidal anti-inflammatory drugs (NSAIDs).
Unable or unwilling to take folic acid or vitamin B12 supplementation.
You are unable to take corticosteroids.

Study Phase: Phase III (What are Phases?)

To receive information and updates for this trial:
Please contact us and mention the Trial ID below.

Trial ID (ClinicalTrials.gov): NCT00762034

<< Back to all ClinicAid clinical trials